Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2KVG4
|
|||
| Drug Name |
TRS003
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 3 | [1] | |
| Non-small-cell lung cancer [ICD-11: 2C25] | Phase 3 | [2] | ||
| Company |
Teruisi
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Vascular endothelial growth factor (VEGF) | Target Info | . | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05378867) A Phase 3, Multicenter, Randomized and Double-blind Study Assessing the Interchangeability Between TRS003 and China-approved Bevacizumab? (Also Called China-approved Avastin) For First-Line Treatment of Patients With Metastatic Colorectal Cancer (CRC). U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04416035) A Phase 3, Multicenter, Randomized and Double-Blind Study to Assess the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab in Subjects With Advanced Nonsquamous NSCLC. U.S.National Institutes of Health. | |||
| REF 3 | Prevalence of porcine cysticercosis in Vellore, South India. Trans R Soc Trop Med Hyg. 2013 Jan;107(1):62-4. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.